Article

Iron deficiency and child and maternal health

Center for Human Nutrition, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
American Journal of Clinical Nutrition (Impact Factor: 6.92). 02/2009; 89(3):946S-950S. DOI: 10.3945/ajcn.2008.26692D
Source: PubMed

ABSTRACT Iron deficiency is most commonly found in women of reproductive age and infants worldwide, but the influence of maternal iron deficiency on infant development is underexplored.
The objective was to examine the relation between maternal iron status and mother-child interactions in a randomized, double-blind, intervention trial conducted in South Africa.
Women were recruited into the study from a health clinic at 6-8 wk postpartum and were classified as either iron-deficient anemic (IDA) or iron-sufficient after blood analysis. IDA mothers received iron supplements of 125 mg FeSO(4) (IDA-Fe; n = 34) or placebo (IDA-PL; n = 30) daily from 10 wk to 9 mo postpartum. The control group (n = 31) consisted of iron-sufficient mothers. Free-play mother-child interaction sessions were videotaped in the clinic at 10 wk (n = 80) and 9 mo (n = 66) postpartum and coded per the Emotional Availability Scales (4 maternal scales: sensitivity, structuring, nonintrusiveness, and nonhostility; 2 infant scales: responsiveness and involvement).
At 10 wk, scores for maternal sensitivity and child responsiveness were significantly greater in the control group than in the IDA groups (P = 0.028 and 0.009, respectively). At 9 mo, the control and IDA-Fe groups no longer differed. These 2 groups scored significantly better on the maternal sensitivity, structuring, and nonhostility scales and on the child responsiveness scale than did the IDA-PL group (P = 0.007-0.032), whose iron status remained low.
These data indicate that maternal iron deficiency negatively affects mother-child interactions and that iron supplementation protects against these negative effects.

0 Followers
 · 
83 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Maternal iron status is thought to be related to postpartum depressive symptoms. The purpose of the present study was to evaluate the relationship between pre- and postnatal maternal iron status and depressive symptoms in pilot (n = 137) and confirmatory (n = 567) samples of Chinese women. Iron status was evaluated at mid- and late pregnancy and 3 days postpartum. The Edinburgh Postnatal Depression Scale (EPDS) was used to assess maternal postpartum depression 24-48 hours after delivery and 6 weeks later. In the pilot sample, correlations between early- and late-pregnancy maternal Hb and EPDS scores at 6 weeks were r = 0.07 and -0.01, respectively (nonsignificant). In the confirmatory sample, the correlations between maternal iron measures (Hb, MCV, ZPP, ferritin, sTfR, and sTfR Index) in mid- or late pregnancy or 3 days postpartum and EPDS scores shortly after delivery or at 6 weeks were also low (r values < 0.10). EPDS scores in anemic and nonanemic mothers did not differ, regardless of sample or timing of maternal iron status assessment. In addition, women with or without possible PPD were similar in iron status in both samples. Thus, there was no relationship between maternal iron status and postpartum depression in these samples.
    Journal of pregnancy 07/2012; 2012:521431. DOI:10.1155/2012/521431
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Iron deficiency (ID) anemia is associated with poor neurocognitive development in infants and children. Depending on the stage of development at the time of deficiency, these adverse effects may be reversible. Recent investigations using sensitive measurements have confirmed that the deposition of iron in the brain varies according to brain region and age, and that dopamine-dependent behaviors are among the core deficits in ID. Dr John Beard (1947-2009) has been one of the leading scientists and pioneers in the area of iron and child development. His legacy to this area of science will grow through the continuation of his work by his co-workers and colleagues.
    Nutrition Reviews 11/2010; 68 Suppl 1:S48-52. DOI:10.1111/j.1753-4887.2010.00331.x · 5.54 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: RésuméLes principales causes de la carence en fer (CF) sont brièvement discutées, puis un examen des études s’intéressant à la CF et classées en fonction de leur méthodologie et design, a été réalisé, à la recherche de liens de causalité entre la CF et le comportement et le développement cognitif et moteur de l’enfant. L’anémie ferriprive (AF) est associée à de nombreux problèmes psychosociaux et économiques qui peuvent affecter le développement de l’enfant et pourraient expliquer la relation, souvent observée, entre AF et troubles du développement et du comportement. De nombreuses données indiquent des modifications du fonctionnement cérébral chez les nourrissons présentant une AF. Cependant, de nombreux essais visant à traiter la CF manquent de puissance statistique en raison d’un faible effectif, de l’inclusion d’enfants non carencés, ou d’un traitement induisant peu ou pas de différence sur le statut ferrique entre le groupe placebo et le(s) groupe(s) traité(s). Chez les enfants de moins de 3 ans présentant une AF, les essais randomisés indiquent qu’une complémentation en fer est généralement bénéfique pour le développement moteur, mais pas nécessairement pour le développement mental. Une complémentation en fer a également des effets bénéfiques sur la fonction cognitive chez les enfants en âge scolaire présentant une AF. Il ne semble pas exister de seuil au-delà duquel une CF affecterait le développement de l’enfant, mais ceux dont la CF est suffisemment importante pour provoquer une AF devraient bénéficier en priorité d’une complémentation en fer. Cependant, les effets délétères d’une complémentation martiale sur la croissance et la morbidité chez des enfants non carencés doivent être pris en considération lors de l’élaboration de tels programmes interventionnels ou de politiques de santé publique.
    Annales Nestlé (Ed française) 01/2010; 68(3). DOI:10.1159/000328758